{"entity":{"id":"nct06088290","kind":"trial","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","aka":["SaLuDo"],"tldr":"A phase 3 trial of Lurbinectedin and Doxorubicin in uterine sarcoma, run by PharmaMar, active and no longer recruiting.","summary":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) is a phase 3 interventional study registered as NCT06088290 by PharmaMar, with 469 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2029-08-30. Interventions recorded: Lurbinectedin and Doxorubicin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06088290","url":"https://clinicaltrials.gov/study/NCT06088290"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["uterine-sarcoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["lurbinectedin","doxorubicin"],"companies":["pharmamar"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06088290","phase":"3","setting":"Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma","sponsor":"PharmaMar","participation":[{"nct":"NCT06088290","source":"https://clinicaltrials.gov/study/NCT06088290","fetchedAt":"2026-10-07T16:54:11.803Z","studySha256":"2b1e74c49bb77655d8c7017cf388df123cb4fdac0f9dd42a5583603b6e014eb8","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-18","leadSponsor":"PharmaMar","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":469,"enrolmentType":"ACTUAL","siteCount":97,"recruitingSiteCount":0,"countries":["Austria","Belgium","France","Germany","Italy","Netherlands","Poland","Portugal","Spain","Switzerland","United Kingdom","United States"]}],"started":"2023-09-21","startedType":"actual","enrolled":469,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06088290/","neighbours":{"cancer":[{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/"}],"company":[{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/"}]}}